Work

Abstract RF4-02: Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-rf4-02

Authors: W. Janni, T. Fehm, V. Müller, J. Blohmer, A. De Gregorio, T. Decker, A. Hartkopf, N. Ditsch, M. Schmidt, P. Wimberger, T. Engler, M. Banys-Paluchowski, P. A. Fasching, B. Rack, A. Schneeweiss, K. Pantel, T. W. Friedl, F. Schochter, J. Huober

Institutions: University Hospital Ulm, Düsseldorf University Hospital, University Medical Center Hamburg-Eppendorf, Charité - Universitätsmedizin Berlin, SLK-Kliniken Heilbronn, Universitätsklinikum Tübingen, University of Augsburg, University Hospital Augsburg, University Medical Center of the Johannes Gutenberg University Mainz, University Hospital Carl Gustav Carus, University Hospital Schleswig-Holstein, Universitätsklinikum Erlangen, German Cancer Research Center, Kantonsspital St. Gallen

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129271267

Cites:

Cited by: 2

Related to: